



Atopic Dermatitis Enrollment Form A-H
Physician Offices Call: 855-460-7928
Fax: 888-777-5645

Prescriber:	NPI:
Supervising Physician:	NPI:
Address:	Tax ID:
Phone:	Fax:
Contact:	

PATIENT INFORMATION

Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State:	ZIP:
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____

PRESCRIPTION

Has the patient received a loading dose/starter kit? <input type="checkbox"/> Yes Start Date: ____/____/____ <input type="checkbox"/> No SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____			
Drug		Directions & Quantity	Refills
Adbry®	<input type="checkbox"/> 300 mg Autoinjector	<input type="checkbox"/> INITIAL: Inject 600 mg SQ on day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: 1) <small>***Intended for patients who weigh below 100 kg who achieve clear/almost clear skin after 16 weeks of treatment***</small>	
	<input type="checkbox"/> 150 mg Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 600 mg SQ on day 1 (Quantity: 4) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 4) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: 2) <small>***Intended for patients who weigh below 100 kg who achieve clear/almost clear skin after 16 weeks of treatment***</small>	
Cibinqo®	<input type="checkbox"/> 100 mg Tablet	<input type="checkbox"/> Take 100 mg PO once daily (Quantity: 30)	
	<input type="checkbox"/> 200 mg Tablet	<input type="checkbox"/> Take 200 mg PO once daily (Quantity: 30) <small>***Intended for patients who have not achieved adequate response with 100 mg daily dose***</small>	
Dupixent®	<input type="checkbox"/> 300 mg Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 600 mg SQ on day 1 (Quantity: 2)	
	<input type="checkbox"/> 300 mg Pen	<input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2)	
Ebglyss®	<input type="checkbox"/> 250 mg Pre-filled Syringe <input type="checkbox"/> 250 mg Pen	<input type="checkbox"/> INITIAL: Inject 500 mg (two 250 mg injections) SQ at week 0 & week 2 (Quantity: 4)	
		<input type="checkbox"/> INDUCTION: Inject 250 mg SQ every 2 weeks starting at week 4 (weeks 4-14) (Quantity: 2 plus 2 refills)	
		<input type="checkbox"/> FINAL INDUCTION: Inject 250 mg SQ (week 16) (Quantity: 1)	
		<input type="checkbox"/> MAINTENANCE: Inject 250 mg SQ every 4 weeks (thereafter) (Quantity: 1)	
Eucrisa®	<input type="checkbox"/> 2% Ointment 60 gm <input type="checkbox"/> 2% Ointment 100 gm	<input type="checkbox"/> MAINTENANCE: Inject 250 mg SQ every 8 weeks (thereafter) (Quantity: 1)	
		<input type="checkbox"/> MAINTENANCE: Inject 250 mg SQ every 2 weeks (thereafter) (Quantity: 2)	
		<input type="checkbox"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	

MEDICAL INFORMATION

*****PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY*****

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	<p>Affected Areas</p> <input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: _____ Scoring tool used <input type="checkbox"/> BSA <input type="checkbox"/> EASI <input type="checkbox"/> ISGA <input type="checkbox"/> POEM <input type="checkbox"/> SCORAD % or Score: _____ Allergies: _____
<input type="checkbox"/> Methotrexate	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Cyclosporine	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Tacrolimus	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Elidel	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Protopic	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
PHOTOTHERAPY	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	
<input type="checkbox"/> UVA/UVB	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Patient cannot afford	<input type="checkbox"/> Photosensitivity	<input type="checkbox"/> Risk of Skin Cancer	<input type="checkbox"/> Distance from Office	
<input type="checkbox"/> L20.9 Atopic Dermatitis	<input type="checkbox"/> (Mild to Moderate) <input type="checkbox"/> (Moderate to Severe)	<input type="checkbox"/>	_____	
<input type="checkbox"/> Other: _____	Date of Diagnosis: ____/____/____			
Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____ Hep B ruled out/treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____				

Additional Clinical Information:

INJECTION TRAINING

Patient has received pen and injection training Physician's office to provide injection training Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: _____ **Date:** ____/____/____

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.